GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain
Open Access
- 23 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (9) , e1339-e1345
Abstract
Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing. Implications for Practice: This work presents a set of guidelines regarding available options for breast cancer (BC) patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the suddenness of this health crisis, specialists have to make decisions with little evidence at hand. Thus, these expert guidelines may be a useful tool to facilitate medical decision making in the context of a worldwide pandemic with no resources to spare.Keywords
This publication has 23 references indexed in Scilit:
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)Annals of Oncology, 2018
- Once-Weekly Hypofractionated Radiotherapy for Breast Cancer in Elderly Patients: Efficacy and Tolerance in 486 PatientsBioMed Research International, 2018
- Preoperative breast radiation therapy: Indications and perspectivesEuropean Journal of Cancer, 2017
- Highly Accelerated Irradiation in 5 Fractions (HAI-5): Feasibility in Elderly Women With Early or Locally Advanced Breast CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward TrialRadiotherapy and Oncology, 2016
- Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast CancerJAMA Oncology, 2016
- Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343Journal of Clinical Oncology, 2013
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2013
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor CharacteristicsJNCI: Journal of the National Cancer Institute, 2008
- Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized TrialsJournal of Clinical Oncology, 2001